Sanofi Teams Up with OpenAI and Formation Bio for AI-Driven Drug Development

French drugmaker Sanofi has collaborated with OpenAI and tech-driven pharmaceutical firm Formation Bio to build AI-powered software to fuel drug development. This collaboration will bring together data, software, and tuned models to generate custom, purpose-built solutions across the drug development cycle.

OpenAI will enable access to AI capabilities, including the ability to fine-tune models, deep AI expertise, a dedicated partnership, and resources. Further, Sanofi plans to utilize this collaboration to access proprietary data for developing AI models, aiming to become the first biopharma company extensively powered by AI.

Paul Hudson, CEO of Sanofi, states that the next generation of tailored AI models will be crucial to the mission of revolutionizing drug development and providing innovative treatments.

Brad Lightcap, COO of OpenAI, says, “There is massive potential for AI to accelerate drug development. We are excited to collaborate with Sanofi and Formation Bio to help patients and their families by bringing new medicines to market.”

Moreover, Formation Bio will contribute engineering resources, expertise in the intersection of pharma and AI, and its platform to design, develop, and implement AI technologies across the pharma lifecycle.

Benjamine Liu, Co-Founder and CEO of Formation Bio, notes, “By creating and implementing customized AI agents and models designed for our industry, companies like Sanofi and Formation Bio can begin to scale with unprecedented productivity and transform the pace at which we bring new medicines to patients.”